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INTRODUCTION 
In this brief review, I will give an account of what has 
happened in the field of liver transplantation in the last 32 years 
and comment on the prospects for the transplantation of gastro-
intestinal organs, to be specific, of the intestines. 
Case Report 
Liver replacement always has been the most interesting of the 
transplant procedures. Let me start by illustrating with a case 
report what a powerful tool for scientific inquiry a liver 
transplantation can be. 
A tiny child was seen shortly after birth at the Mount Sinai 
Hospital in New York City. The baby was lethargic, with convulsions 
and a blood ammonia of over 1000 ]1H/ml. The hyperarrunonemia 
immediately suggested the diagnosis of urea cycle enzyme deficiency. 
Although at least a half dozen hepatic mitochondrial and cytosolic 
enzymes are involved in the urea cycle, it seemed most likely that 
the child had a carbamyl synthetase deficiency. Since the liver is 
the sale, or almost the sole, site of the conversion of ammonia into 
urea, several years ago, Dr. Leon Rosenberg, Dean of the Yale 
University School of Medicine, had suggested to me the use of liver 
transplantation to treat patients with this inborn error of 
metabolism. Unfortunately, it was never possible to keep patients 
with this diagnosis alive for long enough after their birth to obtain 
an adequate donor liver. The baby in question was treated with 
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infusions that encourage alternative pathways of ammonia metabolism, 
allowing survival for 15 days. The transplantation was performed 
successfully with a newborn liver. Within a few hours the patient 
became metabolically normal. 
Other Inborn Errors 
This case report illustrates how expansive the indications 
have become for liver transplantation. Nearly a dozen inborn 
errors of metabolism have been somatically corrected with a new 
liver, including the clotting disorders of hemophilia (1) and 
protein C deficiency (2). The history of the inborn errors of 
metabolism is itself a fascinating one. The first such disease in 
which the pathogenesis was defined by a specific enzyme deficiency 
was Type I glycogen storage disease (glucose-6-phosphatase 
deficiency). This was only in 1956. The authors of this work were 
the Coris, husband and wife, and Illingworth of Saint Louis. 
A Coincidence of Timing 
In that same year, 1956, there was no journal dedicated to 
transplantation. Most of the few papers on transplantation were 
published either in the Bulletin of the New York Academy of Sciences 
or in the Transplantation Bulletin. The latter was an appendage to 
the journal, Plastic and Reconstructive Surgery. The first mention 
of liver transplantation was in an abstract in the Transplantation 
Bulletin. The article did not have a title and did not contain any 
indication of the animal species in which the transplantation was 
performed (3). Cannon suggested that transplantation might have 
clinical relevance in the future. He mentioned lung, liver, kidney, 
heart, and intestines as candidate organs for eventual transplan-
tation. He also recognized that organ preservation would have to 
be developed before the clinical application of any of these 
organs could be considered. 
Transplantation of tissues and organs was not a hot academic 
topic in the years 1955-60. During this period, the annual meetings 
of the Society of University Surgeons were almost void of this topic. 
Only seven articles on transplantation were presented throughout the 
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half-decade, and none with any lasting impact. One article by 
David Hume described the wrapping of transplanted kidneys in plastic 
bags to prevent contact with the recipient tissues. One discussed 
the effect of pyridoxine deficiency on rejection. In a deja vu 
article published in Science, 1988, Schreiner et al. have reevaluated 
the possibility of reducing macrophage activity by starvation of the 
recipient to ensure allograft acceptance. Dr. Robert Good and his 
colleagues from Minnesota focused on the possibility of inducing 
tolerance. 
Transplantation was thought to be completely impractical until 
the early 1960's. In January 1961, roughly at the time of 
President John Kennedy's inauguration, the New England Journal of 
Medicine published an article by Sir Macfarlane Burnet (4) who wrote 
"much thought has been given to ways by which tissues or organs not 
genetically and antigenically identical with the patient might be 
made to survive and function in the alien environment. 
the present outlook is highly unfavorable to success . 
On the whole, 
" 
Burnet's words were hardly on paper before new insight was 
gained in several aspects of transplantation, which would make 
feasible the clinical grafting of kidneys and later of the liver and 
the heart. These advances in knowledge developed in three distinct 
areas; first, immunosuppression; second, organ preservation; and 
third, histocompatibility. These are the "struts" of the clinical 
discipline of transplantation. 
STATE OF ART 
Immunosuppression 
In 1959 and 1960, the immunosuppressive qualities of 
6-mercaptaopurine and azathioprine were described by Schwartz and 
Damashek (5). This was the beginning of the so-called era of immuno-
suppression. Although individual agents could not prevent 
rejection reliably or completely, combination therapy with azathio-
prine and prednizone opened the doors for widespread clinical 
application of renal transplantation (6). In 1966, antilymphocyte 
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serum (ALS) and its globulin derivitive (ALG) were introduced as 
immunosuppressive adjuncts (7). A giant leap forward was made 
possible by the discovery (8) and then clinical application of 
Cyclosporin A (9). 
Even though Cyclosporin A has been proved to be highly nephro-
toxic when used alone in large doses, combining it with other drugs 
brought impressive improvements in immunosuppressive therapy (10). 
After introduction of this drug for liver transplantation, the one-
year survival doubled and, in succeeding years, the advantages 
became even greater. In 1981, Cosimi et al. (11) of Boston added 
another weapon to the therapeutic armamentarium, namely a modern-
day ALG, which is a murine monoclonal antibody (OKT3) directed 
against mature lymphocytes. 
In the early years of clinical application, the kidney was the 
only whole organ transplanted. In 1963, the first attempts were 
made to transplant the liver (12). Four of the first five patients 
survived the operation, but the maximum survival was only 23 days. 
Nevertheless, the principles of orthotopic liver transplantation 
were nearly completely delineated. The first prolonged human 
survivals were achieved in 1967 under treatment with azathioprine, 
prednisone, and ALG (13). What has happened since has made liver 
transplantation a service that has changed the practice of 
hepa to logy (14). 
FK 506 
Despite its impressive advantages for immunosuppressive therapy 
in transplantation, cyclosporine still poses serious problems. 
Therapeutic doses of cyclosporine, even given in the framework of 
combination therapy with steroids and other drugs, can lead to 
kidney damage. On the other hand, lowering the doses excessively 
may allow allograft rejection. Therefore, a search for new drugs 
has powerful incentives. 
At the transplantation congress in Helsinki in August 1986, 
a small but interested audience listened to the description, for the 
first time (15), of a new immunosuppressive agent termed "FK 506", 
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which was developed by the Fujisawa Corp., Osaka, Japan. This 
compound is not related chemically to Cyclosporin A. On a weight 
basis, its activity is 500 times greater than that of Cyclosporin A. 
FK 506 was purified from a culture of a species of Streptomyces 
isolated from soil collected 40 kilometers from Tokyo. 
In an impressively short time, the physicochemical and immuno-
logic properties of FK 506 were elucidated/and a monograph with a 
vast amount of clinically relevant experimental information was 
published as a supplement to Transplantation Proceedings (16). This 
illustrated how fast a discovery of basic biologic sciences now-a-
days c~n be ready for clinical application. With FK 506, the latent 
period between discovery of FK 506 and its first clinical trials 
probably will be less than five years, far shorter than with any 
previous immunosuppressive agent. The physicochemical properties 
of FK 506 are similar in many aspects to those of Cyclosporin A. 
The effects of FK 506 on experimental kidney and liver transplan-
tation compare favorably to those of Cyclosporin A (17). 
Of exceptional interest is the synergism of FK 506 with 
Cyclosporin A. This synergism has been easy to study in a mixed 
lymphocyte culture assay system developed by Dr. Adrienna Zeevi in 
our laboratories (18) and called a mini transplantation system. The 
quantitative data obtained in Zeevi's well-controlled in vitro 
system are much more reliably and readily obtained than with any 
system in the past. Test results with this in vitro method can 
then be verified with classical in vivo heart, kidney, and liver 
transplant models in different animal species (16, 17). 
Using Zeevi's assay system for lymphocytes from human homograft 
biopsies, it has been possible to identify distinct clones of 
cyclosporine-sensitive and resistant cells, and to show that very 
low doses of FK 506 and Cyclosporin A, which by themselves do not 
induce immunosuppression, have a convincing immunosuppressive effect 
when given together. 
It is also highly promising that short courses of FK 506 may 
have long-lasting effects on graft rejection. Such long-lasting 
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immunosuppression in dogs after brief time treatment has been 
reported in the past only with antilymphocyte serum (ALS). In dogs 
treated on days 4, 5, and 6 after grafting of allogeneic kidneys -
i.e. at a time when, without treatment, histological and biochemical 
signs of rejection can be seen - acceptance of grafts was observed 
in 50% of the animals for prolonged periods of time. Some of the 
dogs have had a functioning kidney graft for over six months (17). 
The same has been achieved with livers (17). 
The results of toxicity studies on FK 506 can be summarized as 
follows. There is toxicity in dogs: intussusception of intestines 
and systemic arteritis have been described. However, even without 
FK 506 treatment, arteritis occurs in dogs after transplantation 
(17). In rats and baboons, FK 506 seems to have only minor toxic 
effects (17). 
Concentration of FK 506 can be determined efficiently and 
reliably in plasma and in tissues. Monoclonal antibodies to FK 506 
are being used in highly sensitive and specific assays. 
Organ Preservation 
Dr. Henry Swan of the University of Colorado was the first to 
minimize tissue injury during cessation of circulation for open 
heart surgery. In 1959, while in Chicago, I perfused livers with 
cold lactated Ringer's solution before their experimental 
transplantation in animals. In 1966, Christian Barnard and his 
colleagues developed the first ex vivo perfusion system for kidneys, 
using cold blood and a hyperbaric oxygen chamber. This was a major 
achievement on the road to clinically useful preservation of organs. 
Later, Dr. Fred Belzer removed the blood using an asanguinous 
perfusate which he had developed. In 1976, the introduction of a 
chilled high potassium electrolyte (Collin's) solution allowed 
preservation of human livers for 6 to 8 hours and opened the 
possibility of transporting cadaveric livers from city to city. 
A quantum leap in liver preservation was achieved recently by 
Dr. Belzer, mentioned above, with a modified infusion solution. The 
effectiveness of this solution and its composition were reported 
last September (1987) in a Pittsburgh transplant conference (19). 
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The contribution of the various components of the solution to its 
effectiveness still is poorly understood, but it seems that 
raffinose and lactobionate (two sugars) are the most important 
ingredients. The use of this infusion solution allows livers to be 
preserved for 24 to 30 hours, a capability that has revolutionized 
liver transplantation (20). In Todo's studies, SGOT-level and 
prothrombin-time increases after transplantation showed no correla-
tion with the time of tissue preservation (20). It should now be 
possible to exchange donor livers between Europe, Canada, the United 
States and South America and even with countries as far away as 
Australia, New Zealand and most of Southeast Asia. 
We hope that in the near future, preservation of livers for 
a week or more will become feasible. 
Tissue Matching 
The role of histocompatibility antigens, encoded by genes of 
the MHC on chromosome 6, had been predicted by Jean Dausset and 
Paul Terasaki to be a crucial determinant of success in transplan-
tation. However, the relevance of these antigens for "classical" 
allograft rejection has become small because of the availability of 
potent immunosuppressive drugs. On the other hand, crossmatching 
has become increasingly important in kidney transplantation in view 
of hyperacute rejection of renal homografts to recipients possessing 
antigraft cytotoxic antibodies. Cyclosporin A and other immuno-
suppressive drugs do not influence the hyperacute rejection. 
The first examples of hyperacute rejection caused by 
isoagglutinins were reported by us 25 years ago. The first patient 
with blood group 0 received a kidney from a blood group A donor. 
Within a few minutes, the kidney was destroyed. Other such 
experiences dictated the blood group schemes in use today for donor 
recipient matching. These are designed to avoid placing organs 
into a recipient whose plasma contains. antigraft antibodies (21). 
Terasaki reported in 1965 on a hyperacute kidney rejection in 
a patient whose serum contained cytotoxic antibodies directed 
against the recipient (22). W. J. Dempster had shown hyperacute 
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rejection of kidneys in presensitized dogs as early as 1955 (23). 
The term hyperacute rejection was coined by Kissmeyer-Nielsen much 
later (24). With hyperacute rejection, the microvasculature is 
ruined. Small vessels are plugged with blood cells, neutrophils, 
and fibrin. These changes result in acute cortical necrosis of the 
kidney. Felix Milgrom emphasized the pivotal role of antibodies in 
hyperacute rejection. Ito et al.in 1985, also working in Buffalo, 
analyzed the involvement of various humoral mediators of 
inflammation in hyperacute rejections (25). Ito's preoccupation 
was with platelet activating factor (PAF). 
Whereas kidneys usually are destroyed in 2-3 minutes after 
grafting to a highly sensitized recipient, the liver seems to be much 
more resistant to this type of rejection. There is little correla-
tion of outcome of liver transplantation with or without cytotoxic 
crossmatches with the donor. Even the presence of immunoglobulins 
picked up in the liver is poorly correlated with rejection of the 
organ. If hyperacute rejection occurs, it may present as a 
hemorrhagic necrosis developing at a much slower pace (over 2-3 
days) than the hyperacute rejection of the kidney. 
Transplantation of Intestines 
Until recently, clinical intestinal transplants have not been 
performed successfully, i.e., with a functional intestine after 
grafting. Twenty-five years ago, I developed a surgical procedure 
by which all of the abdominal viscera were transplanted (liver, 
stomach, pancreas, spleen, small intestine,and most of the colon) 
(26) . 
Last November 1, an infant was treated at our clinic who had 
lost all of her midgut but who had survived with the shortgut 
syndrome for 2.5 years on parenteral hyperalimentation. She then 
developed irreversible liver disease. We decided to attempt the 
same transplantation of multiple viscera which had been worked out 
in animals in 1960. A donor was available 407 miles from Pittsburgh. 
We treated the donor with OKT3. Later, Shaffer et al. (27) reported 
that donor pretreatment with ALS in rats completely abolished the 
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undirectional graft versus host reaction (GVH) of their experimental 
model. 
Our patient never had evidence of GVH disease. The intake of 
nutrients through the intestinal graft improved over time, so that 
hyperalimentation could be reduced and ultimately almost completely 
stopped (28). Gastrointestinal x-ray series showed a normal transit 
time. Biopsies of intestines were normal. Three months after 
treatment, however, the liver became the site of lymphomas 
associated with an Epstein Barr virus (EBV) infection (29). These 
lymphoproliferative tumors of the liver had both monoclonal and 
polyclonal components and were of recipient origin. Cyclosporin A 
was discontinued. The cyclosporine levels in circulation decreased, 
and the liver lesions resolved with calcification of the lesional 
margins. 
Cyclosporin A was then reinstituted, and the lesions started 
to grow again, compressing the biliary ducts. We could decompress 
partially the duct system, but just as we considered retransplan-
tation of the liver, the child died of bacterial sepsis. Even 
though the transplantation eventually was thwarted by the 
destructive liver lesions, and the patient was lost, the parents 
of the child may find some consolation in the memory that 
everything possible was attempted. The surgical and pediatric 
teams were encouraged by the fact that the transplanted intestines 
functioned impressively in the child for many months. 
Of this child, and other patients who have been the 
pioneers of transplantation technology in the last 30 years, it can 
be said that: "Diseases desperate grown by desperate appliance are 
reliev'd or not at all" (Claudius, in "Hamlet"). 
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